ArriVent BioPharma, Inc. Common Stock (AVBP) — Financial Flexibility Index
ArriVent BioPharma, Inc. Common Stock (AVBP) has a Financial Flexibility Index of -1.65x as of March 2026. Free cash flow of $-41.89 Million (operating CF $-41.89 Million minus capex $0.00) represents -2% of total liabilities ($25.32 Million). Also explore ArriVent BioPharma, Inc. Common Stock equity growth rate to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
ArriVent BioPharma, Inc. Common Stock Financial Flexibility Index (2021–2025)
Historical Financial Flexibility Index trend for ArriVent BioPharma, Inc. Common Stock across 5 annual periods. Check AVBP PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for ArriVent BioPharma, Inc. Common Stock (2021–2025)
Year-by-year free cash flow to debt coverage for ArriVent BioPharma, Inc. Common Stock. For the full company profile including market capitalisation, see market value of ArriVent BioPharma, Inc. Common Stock.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -6.19x | $-160.59 Million | $-160.59 Million | $25.95 Million | ▼ -52.4% |
| 2024 | -4.06x | $-70.21 Million | $-70.21 Million | $17.29 Million | ▲ +14.2% |
| 2023 | -4.73x | $-55.84 Million | $-55.84 Million | $11.80 Million | ▲ +9.2% |
| 2022 | -5.21x | $-43.63 Million | $-43.63 Million | $8.37 Million | ▲ +24.7% |
| 2021 | -6.92x | $-12.59 Million | $-12.59 Million | $1.82 Million | — |